Evidence map›Paper›PMID 34177409›Full record

ArticleEXCLI journal2021

The involvement of small heat shock protein in chemoresistance in ovarian cancer -

Aleksandra Wyciszkiewicz, Michal S Lach, Joanna P Wróblewska, Marcin Michalak, Wiktoria M Suchorska, Alicja Kalinowska, Slawomir Michalak

Open access · greenAbstract read
In one paragraph

Article in EXCLI journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Medicina (Kaunas, Lithuania) · 2023
    Article
  7. Angiotensin-converting enzyme inhibitors for ovarian cancer? - a new adjuvant option or a silent trap.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Aleksandra WyciszkiewiczDepartment of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, Poland.
Michal S LachRadiobiology Laboratory, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznań, Poland.ORCID https://orcid.org/0000-0002-3615-3768
Joanna P WróblewskaDepartment of Tumor Pathology and Prophylaxis, Poznań University of Medical Sciences, Garbary 15, 61-866 Poznań, Poland.
Marcin MichalakSurgical, Oncological, and Endoscopic Gynaecology Department, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznan, Poland.
Wiktoria M SuchorskaRadiobiology Laboratory, Greater Poland Cancer Centre, Garbary 15, 61-866 Poznań, Poland.
Alicja KalinowskaDepartment of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, Poland.
Slawomir MichalakDepartment of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, Poland.
Poznan University of Medical Sciences · PLGreater Poland Cancer Center · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is the most deadly gynecologic malignancy worldwide. Although the primary response to chemotherapy is high, the majority of patients will develop resistance against applied treatment. In this study, we focused on resistance to cisplatin, a first-line drug used for the treatment of ovarian cancer. The mechanism of the resistance development process is widely described, but there is a lack of information about the involvement of members of small heat shock proteins (HSPs) and their transport via exosomes. In this study, we used two cell lines: A2780 and SKOV3, and their cisplatin-resistance variants: A2780 CDDP and SKOV3 CDDP. We have shown that the expression of three small HSPs (HSPB5, HSPB6, and HSPB8) in cisplatin-resistant cell lines differs from their sensitive counterparts. Further, we isolated exosomes and determined the small HSPs in their cargo. In A2780 WT we observed a low amount of HSPB5 and HSPB6. We did not observe the expression of small HSPs in the SKOV3 cell line in both sensitive and resistant variants. Our data suggest the involvement of small HSPs in drug resistance of ovarian cancer and their presence is not related to exosomal transport. Analysis of the biological consequences of the imbalance of small HSPs expression in cisplatin resistance needs further investigation.

Indexed as

chemoresistanceexosomesovarian cancersmall HSPs

Identifiers

PMID34177409
PMCPMC8222634
OpenAlexW3173855247

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.